智通财经网·2026-03-24 05:51Core Viewpoint - Citigroup has downgraded the revenue forecasts for China National Pharmaceutical Group (国药控股) by 3% and 4% for the next two years, reflecting the latest guidance from management, and has also reduced the earnings per share forecast by 5% for both years, lowering the target price from HKD 23 to HKD 22.8 while maintaining a "Buy" rating [1] Group 1: Revenue and Earnings Forecasts - The revenue forecasts for China National Pharmaceutical Group have been reduced by 3% and 4% for the current and next year respectively [1] - The earnings per share forecasts have been adjusted downwards by 5% for both years [1] - The target price has been lowered from HKD 23 to HKD 22.8 [1] Group 2: Business Performance and Strategy - Management expects the pharmaceutical distribution business to remain flat year-on-year, while the medical device distribution and retail business is anticipated to recover further, showing positive growth [1] - The company aims to position itself as the cornerstone of the "1+4+x" strategy of China National Pharmaceutical Group, emphasizing its foundational role in the healthcare ecosystem [1] - The company plans to transform its business model to provide more comprehensive services across the entire value chain, supporting the launch of innovative drugs and accelerating hospital access [1] Group 3: Financial Metrics and Operational Insights - The retail business experienced a growth of 9.9% in the second half of last year, primarily driven by a 15% year-on-year increase in professional pharmacy sales [1] - The revenue decline in the medical device distribution business narrowed to 1.6% in the second half of the year [1] - The pharmaceutical distribution business saw a sales decline of 2%, impacted by the expansion of centralized procurement and price reductions from national medical insurance negotiations [1] - Service revenue, including CSO, SPD, and third-party logistics services, grew by 5% year-on-year to RMB 17 billion [1] Group 4: Accounts Receivable Management - The accounts receivable turnover days for China National Pharmaceutical Group extended to 130 days last year [2] - Management is confident in controlling accounts receivable over the next five years, benefiting from the anticipated full implementation of direct and immediate settlement policies in healthcare [2] - Improvements in hospital financial conditions, strict internal controls, and local government efforts to reduce leverage are expected to enhance payment liquidity in the healthcare ecosystem [2]